Cover Image
市場調查報告書

類鴉片物質誘發性便秘的全球市場:2015∼2019年

Global Opioid-Induced Constipation Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 334065
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
類鴉片物質誘發性便秘的全球市場:2015∼2019年 Global Opioid-Induced Constipation Market 2015-2019
出版日期: 2015年07月01日 內容資訊: 英文 69 Pages
簡介

類鴉片物質投予癌症之外的慢性疼痛和急性疼痛病的患者,不過以類鴉片物質誘發性便秘等為首對腸胃有重大的不良影響。類鴉片物質誘發性便秘,可隨著標靶治療和其他的OTC藥的服用透過改善生活習慣來管理。全球類鴉片物質誘發性便秘市場,預計2014∼2019年以年複合成長率30.18%擴大。

本報告提供全球類鴉片物質誘發性便秘市場相關詳細分析、市場趨勢與2015∼2019年的成長預測、各作用機制、各給藥途徑、各劑型、各地區趨勢,及主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 簡稱清單

第3章 本報告的範圍

第4章 產品簡介

  • Amitiza
  • Movantik/Moventig
  • Relistor

第5章 市場調查方法

第6章 簡介

第7章 疾病概要

  • 類鴉片物質誘發性便秘的理解
  • 症狀
  • 病理學
  • 流行病學
  • 診斷
  • 治療和管理

第8章 產品研發線

  • 開發平台分子相關重要資訊

第9章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第10章 各作用機制市場區隔

第11章 各給藥途徑市場區隔

  • 口服
  • 非口服

第12章 各劑型市場區隔

  • 固態
  • 液狀

第13章 各地區市場區隔

第14章 購買標準

第15章 市場成長的促進要素

第16章 促進要素與其影響

第17章 市場課題

第18章 促進要素與課題的影響

第19章 市場趨勢

第20章 趨勢與其影響

第21章 供應商環境

  • 競爭模式
  • 市場佔有率調查:2014年
  • 其他具未來性的供應商

第22章 主要供應商調查

  • AstraZeneca plc
  • 武田藥品工業株式會社

第23章 本系列的其他報告

圖表

目錄
Product Code: IRTNTR6305

About Opioid-induced Constipation

Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation. The opioid analgesics produce analgesia by the activation of the mu receptors found in the CNS and PNS. These drugs affect the motility, tone, and contractility of the bowel functions, which results in the delay in the transit of fecal contents. The opioids also cause a reduction in the secretion of digestive enzymes and also cause partial gastroparesis. Some of the common symptoms of opioid-induced constipation are hard and dry stools, painful defecation, bloating, distention and bulged abdomen, feeling lethargic, and loss of appetite. Opioid-induced constipation can be managed by changing lifestyle along with the use of targeted therapies and other OTC and off-label drugs.

Technavio's analysts forecast the global opioid-induced constipation market to grow at a CAGR of 30.18% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the global opioid-induced constipation market for 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of opioid-induced constipation, which includes branded drugs, off-label products, and OTC drugs.

On the basis of the mechanism of action of drugs, the market is grouped into the following categories:

  • Peripherally Acting Mu-opioid Receptor Antagonist
  • Locally Acting Chloride Channel Activator
  • Others

On the basis of the route of administration of drugs, the market is grouped into the following categories:

  • Oral
  • Parenteral

On the basis of the dosage form of drugs, the market is grouped into the following categories:

  • Solid
  • Liquid

Technavio's report, Global Opioid-induced Constipation Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • AstraZeneca
  • Takeda Pharmaceutical
  • Valeant Pharmaceuticals International

Other Prominent Vendors

  • Abbott
  • Bayer
  • Boehringer Ingelheim
  • C.B. Fleet
  • Cosmo Pharmaceuticals
  • Daewoong
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Ironwood Pharmaceuticals
  • Johnson & Johnson
  • Merck
  • Mundipharma
  • Nektar Therapeutics
  • Pfizer
  • Progenics Pharmaceuticals
  • Shionogi
  • SLA Pharma
  • Sucampo
  • Synergy Pharmaceuticals
  • Theravance

Market Driver

  • Unmet Medical Needs
  • For a full, detailed list, view our report

Market Challenge

  • Availability of OTC and Off-label Drugs
  • For a full, detailed list, view our report

Market Trend

  • Shift to Targeted Therapy
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Amitiza
    • 04.1.2. Movantik/Moventig
    • 04.1.3. Relistor

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Disease Overview

  • 07.1. Understanding Opioid-induced Constipation
  • 07.2. Symptoms
  • 07.3. Pathophysiology
  • 07.4. Epidemiology
  • 07.5. Diagnosis
    • 07.5.1. Patient History
    • 07.5.2. Bristol Stool Form Scale
    • 07.5.3. Physical Examination
    • 07.5.4. Laboratory Tests
    • 07.5.5. Further Investigational Procedures
  • 07.6. Treatment and Management
    • 07.6.1. Pharmacotherapeutic Approach
    • 07.6.2. Non-pharmacotherapeutic Approach

08. Pipeline Portfolio

  • 08.1. Key Information of Pipeline Molecules
    • 08.1.1. Naldemedine
    • 08.1.2. Linaclotide
    • 08.1.3. Axelopran/TD-1211
    • 08.1.4. SP-333
    • 08.1.5. Oral Naloxone

09. Market Landscape

  • 09.1. Market Overview
  • 09.2. Market Size and Forecast
  • 09.3. Five Forces Analysis

10. Market Segmentation by Mechanism of Action

  • 10.1. Peripherally Acting Mu-opioid Receptor Antagonist
  • 10.2. Locally Acting Chloride Channel Activator
  • 10.3. Others

11. Market Segmentation by Route of Administration

  • 11.1. Oral
  • 11.2. Parenteral

12. Market Segmentation by Dosage Form

  • 12.1. Solid
  • 12.2. Liquid

13. Geographical Segmentation

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
    • 21.1.2. Mergers and Acquisitions
  • 21.2. Market Share Analysis 2014
    • 21.2.1. Takeda Pharmaceutical
    • 21.2.2. Valeant Pharmaceuticals International
    • 21.2.3. AstraZeneca
  • 21.3. Other and Future Prominent Vendors

22. Key Vendor Analysis

  • 22.1. AstraZeneca plc
    • 22.1.1. Key Facts
    • 22.1.2. Business Overview
    • 22.1.3. Business Segmentation by Revenue 2013
    • 22.1.4. Business Segmentation by Revenue 2011-2013
    • 22.1.5. Sales by Geography
    • 22.1.6. Business Strategy
    • 22.1.7. Key Developments
    • 22.1.8. SWOT Analysis
  • 22.2. Takeda Pharmaceuticals
    • 22.2.1. Key Facts
    • 22.2.2. Business Overview
    • 22.2.3. Business Segmentation by Revenue 2013
    • 22.2.4. Business Segmentation by Revenue 2013
    • 22.2.5. Geographical Segmentation by Revenue 2013
    • 22.2.6. Business Strategy
    • 22.2.7. Recent Developments
    • 22.2.8. SWOT Analysis
  • 22.3. Valeant Pharmaceuticals International
    • 22.3.1. Key Facts
    • 22.3.2. Business Overview
    • 22.3.3. Business Segmentation by Revenue 2013
    • 22.3.4. Business Segmentation by Revenue 2012 and 2013
    • 22.3.5. Sales by Geography
    • 22.3.6. Business Strategy
    • 22.3.7. Key Developments
    • 22.3.8. SWOT Analysis

23. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Pipeline Drugs: Opioid-induced Constipation
  • Exhibit 3: Snapshot of Global Opioid-induced Constipation Market
  • Exhibit 4: Global Opioid-induced Constipation Market 2014-2019 ($ millions)
  • Exhibit 5: Segmentation of Global Opioid-induced Constipation Market by Mechanism of Action
  • Exhibit 6: Segmentation of Global Opioid-induced Constipation Market by Route of Administration
  • Exhibit 7: Segmentation of Global Opioid-induced Constipation Market by Dosage Form
  • Exhibit 8: Segmentation of Global Opioid-induced Constipation Market by Geography 2014
  • Exhibit 9: Drivers of Global Opioid-induced Constipation Market
  • Exhibit 10: Challenges in the Global Opioid-induced Constipation Market
  • Exhibit 11: Trends of Global Opioid-induced Constipation Market
  • Exhibit 12: Takeda Pharmaceuticals: Key Takeaways
  • Exhibit 13: Valeant Pharmaceuticals International: Key Takeaways
  • Exhibit 14: AstraZeneca: Key Takeaways
  • Exhibit 15: AstraZeneca plc: Business Segmentation by Revenue 2013
  • Exhibit 16: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ million)
  • Exhibit 17: AstraZeneca plc: Sales by Geography 2013
  • Exhibit 18: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013
  • Exhibit 19: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013 (US$ million)
  • Exhibit 20: Takeda Pharmaceuticals: Geographical Segmentation by Revenue 2013
  • Exhibit 21: Valeant Pharmaceuticals International: Business Segmentation by Revenue 2013
  • Exhibit 22: Valeant Pharmaceuticals International: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 23: Valeant Pharmaceuticals International: Sales by Geography 2013
Back to Top